Hyderabad-based active ingredient maker Neuland Laboratories declined to comment on any link between the company's steep rise in share price and Teva getting a priority review status for its experimental drug SD-809. Money Control, 3 weeks ago
3 images for "neuland laboratories"
On 10 February 2017Business Standard, 2 months ago Neuland Laboratories' board meeting on February 10, 2017 Money Control, 2 months ago
on your WebpageAdd Widget >Get your members hooked!